Kanker-actueel Zoledronic acid 4 mg dose gives. given intravenously in randomized phase III trial (1600 patients over 25 months) significantly more effect on bone problems than APD - 90 mg pamidronate. in breast cancer patients and patients

Startpagina

Contact | Disclaimer | Sitehulp

Sitemap | Video's

Patiëntenervaringen | Lotgenotencontact

Forum |

Onze Sponsors

Cancer Types

Regular

Complementary

Coaching

Donations

Questions

Cancer News

Addresses

Prevention

Recipes

Artikelen

= Zometa zoledronic acid immediately after surgery in women with early breast cancer who Femara - Letrozole use provides better protection against bone loss and disease-free time than when Zometa is given only after significant bone loss or fracture occurs. Thus 3-year evaluation of Phase III trial of Z-FAST 602 breast cancer patients. Article updated October 1, 2009.

= Zometa zoledronic acid (a bisphosphonate) receives FDA approval for drug use in bone problems of cancer, including prostate cancer and multiple myeloma patients - Multiple Myeloma patients. Article posted February 2002

= Zometa zoledronic acid provides significantly less risk of breaking bones and better recovery (81%) of bone problems and provides significantly better overall survival in breast, prostate and lung cancer patients compared with botuitzaaiingen APD and placebo, according to three large Phase III trials. Article updated October 1, 2009

= Zometa zoledronic acid (a bisphosphonate) gives 4 mg dose. given intravenously in randomized phase III trial (1600 patients over 25 months) significantly more effect on bone problems than APD - 90 mg pamidronate. in breast cancer patients and patients with MM - Multiple Myeloma (Kahler) Scroll for study reports, etc. Article Update February 22, 2010

= Zometa zoledronic acid (a bisphosphonate) Information: New study shows once again increase our value and effectiveness of Zometa = zoledronic acid compared with APD injections for bone problems of cancer patients

= Zometa zoledronic acid (a bisphosphonate) Information: Zometa provides significantly better results in randomized phase III study in patients with recurrent prostate cancer and as an addition to hormone treatments.

= Zometa zoledronic acid (a bisphosphonate) Information: FDA warns against excessive dose of Zometa for patients with kidney problems. This may not exceed 4 mg. by injection administered.

= Zometa zoledronic acid (a bisphosphonate) information: A survey of three double-blind randomized controlled trials shows that Zometa - zoledronic ACD far better results than APD = pamidronate on bone problems (eg fractures), longer time to first occur and significantly reduces botuitzaaiingen The bone pain in breast cancer, but also in bone metastatic prostate cancer, lung cancer, renal cell cancer and other solid tumors. Article posted October 24, 2005

= Zometa zoledronic acid (a bisphosphonate) shows work best and even cost-effective means to botversterkende against bone loss in solid tumors. Article posted June 30, 2008

= Zometa zoledronic acid (a bisphosphonate) prevents bone loss in women with early breast cancer undergoing chemotherapy, according to randomized placebo-controlled phase III study. Article posted August 23, 2008

Zoledronic acid 4 mg dose gives. given intravenously in randomized phase III trial (1600 patients over 25 months) significantly more effect on bone problems than APD - 90 mg pamidronate. in breast cancer patients and patients with MM - Multiple Myeloma (Kahler)

Zoledronic acid - Zometa significantly prolongs life in patients with multiple myeloma (Multiple Myeloma).

Bisphosphonates often cause bone problems in the jaw - osteonecrosis - evidenced by two recent studies. Article posted February 25, 2011

Zometa - zoledronic acid significantly prevents recurrence in women with breast cancer after the menopause and gives significantly better results in survival, but not in younger women. Estrogen levels appears to play a decisive role. Thus, large phase III study. Article updated March 19, 2011

Bisphosphonates increase in femur fracture risk but this risk does not outweigh benefits of bisphosphonates, according to major Swedish research in breast cancer patients. Article posted May 5, 2011

Learn how Zometa - zoledronic acid can be prescribed and fully compensated and given home can get. Article updated June 8, 2011

Zometa - zoledronic acid in addition to tamoxifen or Armidex disease-free time and better overall survival in breast cancer patients with hormone sensitive breast cancer, shows large randomized phase III study. Article posted June 8, 2011

Zometa - zoledronic acid for breast cancer in algmeen shows no significant positive effect only for postmenopausal women with breast cancer, Zometa in addition to chemotherapy 25 percent longer disease-free and overall survival it. A very special result. Article posted September 27, 2011

Zoledronic acid 4 mg dose gives. given intravenously in randomized phase III trial (1600 patients over 25 months) significantly more effect on bone problems than APD - 90 mg pamidronate. in breast cancer patients and patients with MM - Multiple Myeloma (Kahler)

Zoledronic acid 4 mg dose gives. given intravenously in randomized phase III trial (1600 patients over 25 months) significantly more effect on bone problems than APD - 90 mg pamidronate. in breast cancer patients and patients with MM - Multiple Myeloma (Kahler)